MC

534.2

-1.71%↓

SANES

5.485

-9.22%↓

BNP

68.43

-7.5%↓

CS.FR

37.54

-5.3%↓

ALV

334.5

-5.43%↓

MC

534.2

-1.71%↓

SANES

5.485

-9.22%↓

BNP

68.43

-7.5%↓

CS.FR

37.54

-5.3%↓

ALV

334.5

-5.43%↓

MC

534.2

-1.71%↓

SANES

5.485

-9.22%↓

BNP

68.43

-7.5%↓

CS.FR

37.54

-5.3%↓

ALV

334.5

-5.43%↓

MC

534.2

-1.71%↓

SANES

5.485

-9.22%↓

BNP

68.43

-7.5%↓

CS.FR

37.54

-5.3%↓

ALV

334.5

-5.43%↓

MC

534.2

-1.71%↓

SANES

5.485

-9.22%↓

BNP

68.43

-7.5%↓

CS.FR

37.54

-5.3%↓

ALV

334.5

-5.43%↓

Search

Grifols SA

Cerrado

SectorFinanzas

8.132 -3.28

Resumen

Variación precio

24h

Actual

Mínimo

7.944

Máximo

8.408

Métricas clave

By Trading Economics

Ingresos

17M

69M

Ventas

183M

2B

P/B

Media del Sector

45.229

22.015

BPA

0.101

Margen de beneficios

3.491

Empleados

23,833

EBITDA

57M

482M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+67.3% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

3.3B

6.8B

Apertura anterior

11.41

Cierre anterior

8.132

Noticias sobre sentimiento de mercado

By Acuity

20%

80%

38 / 542 Clasificación en Finance

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

Grifols SA Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

2 abr 2025, 17:19 UTC

Adquisiciones, fusiones, absorciones

Grifols in 'Very Preliminary Talks' With Brookfield Over Renewed Takeover Bid -- 2nd Update

2 abr 2025, 13:02 UTC

Adquisiciones, fusiones, absorciones

Grifols, Brookfield Deny Takeover Talks After Report of Renewed Interest -- Update

2 abr 2025, 10:13 UTC

Adquisiciones, fusiones, absorciones

Grifols Board Denies Media Reports Over Talks With Brookfield for Another Takeover Bid

8 jul 2024, 10:40 UTC

Adquisiciones, fusiones, absorciones

Trending: Grifols Founding Family, Brookfield Eye Takeover Bid for Spanish Drugmaker

8 jul 2024, 09:13 UTC

Adquisiciones, fusiones, absorciones

Grifols Faces Delisting Bid From Founding Family and Brookfield

2 abr 2025, 09:27 UTC

Acciones populares

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

Comparación entre iguales

Cambio de precio

Grifols SA previsión

Precio Objetivo

By TipRanks

67.3% repunte

Estimación a 12 Meses

Media 14.02 EUR  67.3%

Máximo 19.05 EUR

Mínimo 11 EUR

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Grifols SA Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

3 ratings

2

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

8.152 / 8.574Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Weak Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

38 / 542 Clasificación en Finanzas

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Grifols SA

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.